Литература
1. Бенделиани, Н. Г. Влияние оптимизированной многофакторной программы лечения больных с выраженной хронической сердечной недостаточностью на качество их жизни: дис. … канд. мед. наук. - М., 2002. - 125 с.
2. Бокерия, Л. А. Ишемическая болезнь сердца у больных с низкой сократительной способностью миокарда левого желудочка (диагностика, тактика, лечение) / Л. А. Бокерия, В. С. Работников, Ю. И. Бузиашвили и др. - М., 2001. - 195 c.
3. Бокерия, Л. А. Повторные операции у больных ишемической болезнью сердца. Современное состояние проблемы (метаанализ) / Л. А. Бокерия, И. И. Беришвили, И. В. Солнышков и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. - 2009. - Т. 10, № 3.
4. Бокерия, Л. А. Хирургическое лечение постинфарктной аневризмы сердца: прошлое, настоящее и будущее / Л. А. Бокерия, В. С. Работников, М. М. Алшибая, А. В. Дорофеев // Анналы хир. - 2002. - № 3. - C. 23-31.
5. Бокерия, О. Л. Ресинхронизационная терапия при застойной сердечной недостаточности - мнение экспертов и предварительные результаты последних рандомизированных исследований / О. Л. Бокерия // Анналы аритмол. - 2006. - № 1. - C. 11-21.
6. Все о холестерине: национальный доклад / Под ред. акад. РАМН Л. А. Бокерия, акад. РАМН Р. Г. Оганова. - М., 2010. -180 с.
7. Шацкий, А. С. Предикторы сердечной недостаточности и летальности при хирургической коррекции постинфарктных аневризм сердца // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. - 2009. - T. 10, № 3. - C. 53-59.
8. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) / CAPRIE Steering Committee // Lancet. - 1996. - Vol. 348 (9038). - P. 1329-1339.
9. Cameron, A. Bypass surgery with the internal mammary artery graft: 15 year follow-up / A. Cameron, H. G. Kemp Jr, G. E. Green // Circulation. - 1986. - Vol. 74. - P. 30-36.
10. Cavender, J. B. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up / J. B. Cavender, W. J. Rogers, L. D. Fisher et al. // J. Amer. Coll. Cardiol. - 1992. - Vol. 20. - P. 287-294.
11. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial // Lancet. - 1999. - Vol. 353. - P. 9-13.
12. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients / Antiplatelet Trialists Collaboration // Brit. Med. J. - 1994. - Vol. 308 (6921). - P. 81-106.
13. Critchley, J. A. Smoking cessation for the secondary prevention of coronary heart disease / J. A. Critchley, S. Capewell // Cochrane Database of Systematic Reviews. - 2003. - Issue 4.- Art. №: CD003041. DOI: 10.1002/14651858.CD003041.pub2.
14. Davies, E. J. Exercise based rehabilitation for heart failure / E. J. Davies, T. Moxham, K. Rees et al. // Cochrane Database of Systematic Reviews. - 2010. - Issue 4. - Art. №: CD003331. DOI: 10.1002/14651858.CD003331.pub3.
15. Dunning, J. Coronary artery bypass grafting is associated with excellent long-term survival and quality of life: a prospective cohort study / J. Dunning, J. R. Waller, B. Smith et al. // Ann. Thorac. Surg. - 2008. - Vol. 85, № 6. - P. 1988-1993.
16. Ezekowitz, J. A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials / J. A. Ezekowitz, F. A. McAlister // Eur. Heart J. - 2009. - Vol. 30. - P. 469-477.
17. Faris, R. Diuretics for heart failure / R. Faris, M. D. Flather, H. Purcell et al. // Cochrane Database Syst. Rev. - 2006. - № 1: CD003838.
18. Fito, M. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial / M. Fito, M. Guzens, D. Corella et al. // Arch. Intern. Med. - 2007. - Vol. 167. - P. 1195-1203.
19. Fitzgibbon, G. M. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years / G. M. Fitzgibbon, H. P. Kafka, A. J. Leach et al. // J. Amer. Coll. Cardiol. - 1996. - Vol. 28. - P. 616-626.
20. Fox, K. M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. - 2003. - Vol. 362. - P. 782-788.
21. Freemantle, N. Beta-blockade after myocardial infarction: systematic review and meta regression analysis / N. Freemantle, J. Cleland, P. Young et al. // BMJ. - 1999. - Vol. 318. - P. 1730-1737.
22. Garg, R. Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure / R. Garg, S. Yusuf // JAMA. - 1995. - Vol. 273. - P. 1450-1456.
23. Grundy, S. M. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines / S. M. Grundy, J. I. Cleeman, C. N. Merz et al. // Circulation. - 2004. - Vol. 110. - P. 227-239.
24. Held, P. H. Effects of
25. Jolliffe, J. A. Exercise-based rehabilitation for coronary heart disease / J. A. Jolliffe, K. Rees, R. S. Taylor et al. // Cochrane Database Syst. Rev. - 2001. - CD001800.
26. Kim, D. H. Aspirin and clopidogrel use in the early postoperative period following on-pump and offpump coronary artery bypass grafting / D. H. Kim, C. Daskalakis, S. C. Silvestry et al. // J. Thorac. Cardiovasc. Surg. - 2009. - Vol. 138, № 6. - P. 1377-1384.
27. Knatterud, G. L. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial / G. L. Knatterud, Y. Rosenberg, L. Campeau et al. // Circulation. - 2000. - Vol. 102. - P. 157-165.
28. Lie, J. T. Aortocoronary bypass saphenous vein graft atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively / J. T. Lie, G. M. Lawrie, G. C. Morris // Amer. J. Cardiol. - 1977. - Vol. 40. - P. 906-914.
29. McKelvie, R. S. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study / R. S. McKelvie, S. Yusuf, D. Pericak et al. // Circulation. - 1999. - Vol. 100. - P. 1056-1064.
30. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF) // Lancet. - 1999. - Vol. 353. - P. 2001-2007.
31. Nissen, S. E. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial / S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al. // JAMA. - 2004. - Vol. 291, № 9. - P. 1071-1080.
32. Nissen, S. E. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial / S. E. Nissen, S. J. Nicholls, I. Sipahi et al. // JAMA. - 2006. - Vol. 295, № 13. - P. 1556-1565.
33. Packer, M. Effect of carvedilol on survival in sever chronic heart failure (COPERNICUS) // M. Packer, A. J. S. Coats, M. B. Fowler et al. // N. Engl. J. Med. - 2001. - Vol. 344. - P. 1651-1658.
34. Pearson, T. Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia / T. Pearson, M. Denke, P. McBride et al. // Program and abstracts from the American College of Cardiology 53rd Annual Scientific Session. - New Orleans, Louisiana, 2004.
35. Pitt, B. The Captopril-Digoxin Multicenter Research Group study on the comparative steps of captopril and digoxin in patients with mild-moderate heart failure: implications for therapy / B. Pitt, S. Goldstein // Cardiovasc. Drugs Ther. - 1989. - Vol. 3, № 1. - P. 7-9.
36. Schmuziger, M. Reoperative myocardial revascularization: an analysis of 458 reoperations and 2645 single operations / M. Schmuziger, J. T. Christenson, J. Maurice et al. // J. Cardiovasc. Surg. - 1994. - Vol. 2, № 5. - P. 623-629.
37. Shah, S. J. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery / S. J. Shah, D. D. Waters, P. Barter et al. // J. Amer. Coll. Cardiol. - 2008. - Vol. 51, № 20. - P. 1938-1943.
38 Shapira, O. M. Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm / O. M. Shapira, J. D. Alkon, D. S. Macron et al. // Ann. Thorac. Surg. - 2000. - Vol. 70, № 3. - P. 883-888.
39. Squizzato, A. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease / A. Squizzato, T. Keller, S. Middeldorp // Cochrane Database of Systematic Reviews. - 2007. - Issue 3. - Art. №: CD005158. DOI: 10.1002/14651858. CD005158.pub2.
40. Swedberg, K. Candesartan in heart failure-assessment of reduction in mortality (CHARM): rationale and design / K. Swedberg, M. Pfeffer, C. Granger et al. // J. Card. Fail. - 1999. - Vol. 5. - P. 276-282.
41. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) // N. Engl. J. Med. - 1987. - Vol. 316, № 23. - P. 1429-1435.
42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure // N. Engl. J. Med. - 1997. - Vol. 336, № 8. - P. 525-533.
43. The PEACE Trial Investigators. Angiotensinconverting- enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. - 2004. - Vol. 351.- P. 2058-2068.
44. The RALES Investigators. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) // Amer. J. Cardiol. - 1996. - Vol. 78. - P. 902-907.
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure // N. Engl. J. Med. - 1991. - Vol. 325. - P. 293-302.
46. Velazquez, E. J. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry / E. J. Velazquez, G. S. Francis, P. W. Armstrong et al. // Eur. Heart J. - 2004. - Vol. 25, № 21. - P. 1911-1919.
47. Yusuf, S. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients / S. Yusuf, P. Sleight, J. Pogue et al. // N. Engl. J. Med. - 2000. - Vol. 342. - P. 145-153.
48. Zaiac, M. Coronary artery spasm following coronary artery bypass grafting. Treatment with intracoronary ISDN followed by systemic intravenous nifedipine infusion / M. Zaiac, A. Renzulli, C. J. Hilton // Eur. J. Cardiothorac. Surg. - 1990. - Vol. 4, № 2. - P. 109-111.
